Atrial Fibrillation, a common cardiac arrhythmia, is on the rise among older adults, driving the market for AF therapies. DelveInsight’s report highlights 12+ companies and 15+ novel treatments in the pipeline, including promising drugs like Abelacimab, Etripamil, and BAY 3670549. Thryv Therapeutics Inc. received FDA clearance for THRV-1268 in heart failure and AF.

The report provides insights into the global pipeline of AF therapies, showcasing companies like Novartis, HUYA Bioscience, and Milestone Pharmaceuticals. Key takeaways include the initiation of clinical trials with BAY 3670549 by Bayer and positive results from HBI-3000 Phase IIA trial. Novartis’s acquisition of Anthos Therapeutics for abelacimab development is also noted.

AFib affects the heart’s rhythm, leading to irregular heartbeats and potential complications like stroke. Symptoms vary in severity, from palpitations to chest discomfort. Risk factors include high blood pressure, heart diseases, thyroid issues, and age. Diagnosed through tests like ECG, AFib is managed with medications, procedures, and lifestyle changes.

In the realm of AFib treatment, various drugs are being developed by companies like Novartis, HUYA Bioscience, and Verseon. The report covers factors like product type, clinical stage, route of administration, and mechanism of action for these emerging therapies. Companies are striving to address unmet needs in AFib management.

DelveInsight’s Pharma Competitive Intelligence Service offers real-time insights into the competitive landscape of the pharmaceutical industry. Through a tailored approach, clients can access data on emerging drugs, market trends, and competitive strategies to stay ahead. The service is designed to help clients make informed decisions and identify growth opportunities in the market.

Read more at GlobeNewswire: Atrial Fibrillation Clinical Trials & Pipeline Overview: